This project investigates the roles of Regulated in development and DNA damage-response 1 (REDD1) in Hepatocellular carcinoma (HCC). This study aims to assess the effects of liver-specific REDD1 deficiency in HCC tumor progression, microenvironment, and the altered metabolism. State-of-art techniques such as flow-cytometry, qPCR, immunoblot, fluorescent imaging will be used in both mouse, and murine/human hepatic cell models. Overall, this study will potentially clarify the antitumor roles of REDD1 and provide novel insight into altered signaling pathways and metabolism of HCC, which suggests the potential of targeting REDD1 for the development of novel HCC therapies.